Determination of vancomycin pharmacokinetics in neonates to develop practical initial dosing recommendations

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 5, 2014, Pages 2830-2840

  Kim, Julianne ^a   Walker, Sandra A N ^a,b   Iaboni, Dolores C ^a   Walker, Scott E ^a,b   Elligsen, Marion ^a   Dunn, Michael S ^a,c   Allen, Vanessa G ^a,c,d   Simor, Andrew ^a,c  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d PUBLIC HEALTH ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL SKIN DISEASE; BODY WEIGHT; CLINICAL ARTICLE; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG INTERMITTENT THERAPY; FEMALE; HUMAN; INFANT; LOADING DRUG DOSE; MALE; MEDICAL RECORD REVIEW; MONTE CARLO METHOD; NECROTIZING ENTEROCOLITIS; NEWBORN; NEWBORN INTENSIVE CARE; OPTIMAL DRUG DOSE; PERITONEUM EXUDATE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; SEPSIS; SKIN AND SOFT TISSUE INFECTION; SOFT TISSUE INFECTION; STEADY STATE;

ANTI-BACTERIAL AGENTS; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MONTE CARLO METHOD; RETROSPECTIVE STUDIES; VANCOMYCIN;

EID: 84898638462     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01718-13     Document Type: Article

References (49)

1. Stoll BJ, Hansen N, Fanaraoff AA, Carlo WA, Ehrenkranz RA, Lemons JA, Donovan EF, Stark AR, Tyson JE, Oh W, Bauer CR, Korones SB, Shankaran S, Laptook AR, Stevenson DK, Papile LA, Poole WK. 2002. Late-onset sepsis in very low birth weight neonates: the experiences of the NICHD Neonatal Research Network. Pediatrics 110:285-291. http://dx.doi.org/10.1542/peds.110.2.285.
2. Clark R, Powers R, White R, Bloom B, Sánchez P, Benjamin DK, Jr. 2004. Nosocomial infection the NICU: a medical complication or unavoidable problem. J. Perinatol. 24:382-388. http://dx.doi.org/10.1038/sj.jp.7211120.
3. Rubin LG, Sánchez PJ, Siegel J, Levine G, Saiman L, Jarvis WR. 2002. Evaluation and treatment of neonates with suspected late-onset sepsis: a survey of neonatologists' practices. Pediatrics 110(4):e42. http://dx.doi.org/ 10.1542/peds.110.4.e42.
4. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwiwtz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, Rybak MJ, Talan DA, Chambers HF. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin. Infect. Dis. 52:285-292. http://dx.doi.org/10.1093/ cid/cir034.
5. Rybak M, Lomaestro B, Rotschafer J, Moellering R, Jr, Craig W, Billeter M, Dalovisio JR, Levine DP. 2009. Therapeutic monitoring of vancomycin in adult patients: a consensus review of American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am. J. Health Syst. Pharm. 66:82-98. http://dx.doi.org/10. 2146/ajhp080434.
6. Rodvold KA, Everett JA, Pryka RD, Kraus DM. 1997. Pharmacokinetics and administration regimens of vancomycin in neonates, infants and children. Clin. Pharmacokinet. 33:32-51. http://dx.doi.org/10.2165/00003088-199733010-00004.
7. Marsot A, Boulamery A, Bruguerolle B, Simon N. 2012. Vancomycin a review of population pharmacokinetic analyses. Clin. Pharmacokinet. 51: 1-13. http://dx.doi.org/10.2165/11596390-000000000-00000.
8. de Hoog M, Schoemaker RC, Mouton JW, van den Anker JN. 2000. Vancomycin population pharmacokinetics in neonates. Clin. Pharmacol. Ther. 67:360-367. http://dx.doi.org/10.1067/mcp.2000.105353.
9. Capparelli EV, Lane JR, Romanowski GL, McFeely EJ, Murray W, Sousa P, Kildoo C, Connor JD. 2001. The influences of renal function and maturation on vancomycin elimination in newborns and infants. J. Clin. Pharmacol. 41:927-934. http://dx.doi.org/10.1177/00912700122010898.
10. Gabriel MH, Kildoo GC, Gennrich JL, Mondanlou HD, Collins SR. 1991. Prospective evaluation of a vancomycin dosage guidelines for neonates. Clin. Pharm. 10:129-132.
11. Grimsley C, Thomson AH. 1999. Pharmacokinetics and dose requirements of vancomycin in neonates. Arch. Dis. Child. Fetal Neonatal Ed. 81:F221-F227. http://dx.doi.org/10.1136/fn.81.3.F221.
12. James A, Koren G, Milliken J, Soldin S, Prober C. 1987. Vancomycin pharmacokinetics and dose recommendations for preterm infants. Antimicrob. Agents Chemother. 31:52-54. http://dx.doi.org/10.1128/AAC.31.1.52.
13. Kimura T, Sunakawa K, Matsuura N, Kubo H, Shimada S, Yago K. 2004. Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates. Antimicrob. Agents Chemother. 48:1159-1167. http://dx.doi.org/10.1128/AAC.48.4. 1159-1167.2004.
14. Lisby-Sutch SM, Nahata MC. 1988. Dosage guidelines for the use of vancomycin based on its pharmacokinetics in infants. Eur. J. Clin. Pharmacol. 35:637-642. http://dx.doi.org/10.1007/BF00637600.
15. Lo Y-L, van Hasselt JG, Heng SC, Lim CT, Lee TC, Charles BG. 2010. Population pharmacokinetics of vancomycin in premature Malaysian neonates: identification of predictors for dosing determination. Antimicrob. Agents Chemother. 54:2626-2632. http://dx.doi.org/10.1128/AAC.01370-09.
16. McDougal A, Ling EW, Levine M. 1995. Vancomycin pharmacokinetics and dosing in premature neonates. Ther. Drug Monit. 17:319-326. http://dx.doi.org/ 10.1097/00007691-199508000-00001.
17. Reed MD, Kliegman RM, Weiner JS, Huang M, Yamashita TS, Blumer JL. 1987. The clinical pharmacology of vancomycin in seriously ill preterm infants. Pediatr. Res. 22:360-363. http://dx.doi.org/10.1203/00006450-198709000-00024.
18. Mehrotra N, Tang L, Phelps SJ, Meibohm B. 2012. Evaluation of vancomycin dosing regimens in preterm and term neonates using Monte Carlo simulations. Pharmacotherapy 32:408-419. http://dx.doi.org/10.1002/j.1875-9114.2012.01029.x.
19. Patel AD, Anand D, Lucas C, Thomson AH. 2012. Intermittent versus continuous infusion of vancomycin in neonates. Arch. Dis. Child. 97:e20. http://dx.doi.org/10.1136/archdischild-2012-301728.41.
20. Rybak MJ, Lomaetro B, Rotschafer JC, Moellering RC, Craig WA, Billeter M, Dalovisio JR, Levine DP. 2009. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin. Infect. Dis. 49:325-327. http://dx.doi.org/10.1086/ 600877.
21. Pawlotsky F, Thomas A, Kergueris MF, Debillon T, Roze JC. 1998. Constant rate of infusion of vancomycin in premature neonates: a new dosage schedule. Br. J. Clin. Pharmacol. 46:163-167.
22. Plan O, Cambonie G, Barbotte E, Meyer P, Devine C, Milesi C, Pidoux O, Badr M, Picaud JC. 2008. Continuous-infusion vancomycin therapy for preterm neonates with suspected or documented gram-positive infections: a new dosage schedule. Arch. Dis. Child. Fetal Neonatal Ed. 93: F418-F421. http://dx.doi.org/10.1136/adc.2007.128280.
23. Zhao W, Lopez E, Biran V, Durrmeyer X, Fakhoury M, Jacqz-Aigrain E. 2013. Vancomycin continuous infusion in neonates: dosing optimisation and therapeutic drug monitoring. Arch. Dis. Child. 98:449-453. http://dx.doi.org/10.1136/ archdischild-2012-302765.
24. Cataldo MA, Tacconelli E, Grilli E, Pea F, Petrosillo N. 2012. Continuous versus intermittent infusion of vancomycin for the treatment of gram-positive infections: systematic review and meta-Analysis. J. Antimicrob. Chemother. 67:17-24. http://dx.doi.org/10.1093/jac/dkr442.
25. Ingram PR, Lye DC, Tambyah PA, Goh WP, Tam VH, Fisher DA. 2008. Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy. J. Antimicrob. Chemother. 62:168-171. http://dx.doi.org/10.1093/jac/dkn080.
26. James JK, Palmer SM, Levine DP, Rybak MJ. 1996. Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections. Antimicrob. Agents Chemother. 40:696-700.
27. Pea F, Viale P. 2008. Should the currently recommended twice-daily dosing still be considered the most appropriate regimen for treating MRSA ventilatorassociatedpneumoniawithvancomycin? Clin. Pharmacokinet. 47:147-152. http://dx.doi.org/10.2165/00003088-200847030-00001.
28. Rello J, Sole-Violan J, Sa-Borges M, Garnacho-Montero J, Muñoz E, Sirgo G, Olona M, Diaz E. 2005. Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides. Crit. Care Med. 33: 1983-1987. http://dx.doi.org/10.1097/01.CCM.0000178180.61305.1D.
29. Roberts JA, Taccone FS, Udy AA, Vincent JL, Jacobs F, Lipman J. 2011. Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens. Antimicrob. Agents Chemother. 55: 2704-2709. http://dx.doi.org/10.1128/AAC.01708-10.
30. Wysocki M, Delatour F, Faurisson F, Rauss A, Pean Y, Misset B, Thomas F, Timsit JF, Similowski T, Mentec H, Mier L, Dreyfuss D. 2001. Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study. Antimicrob. Agents Chemother. 45:2460-2467. http://dx.doi.org/10.1128/AAC.45.9.2460-2467.2001.
31. Elligsen M, Walker SAN, Simor A, Daneman N. 2012. Prospective audit and feedback of antimicrobial stewardship in critical care: program implementation, experience, and challenges. Can. J. Hosp. Pharm. 65:31-36.
32. de Hoog M, Mouton JW, van den Anker JN. 2004. Vancomycin pharmacokinetics and administration regimens in neonates. Clin. Pharmacokinet. 43:417-440. http://dx.doi.org/10.2165/00003088-200443070-00001.
33. DiPiro JT, Blouin RA, Pruemer JM. 1988. Concepts in clinical pharmacokinetics-A self-instructional course. American Society of Hospital Pharmacists, Bethesda, MD.
34. Lambert RJ, Lambert R. 2006. Population distributions of minimum inhibitory concentration-increasing accuracy and utility. J. Appl. Microbiol. 100:999-1010. http://dx.doi.org/10.1111/j.1365-2672.2006.02842.x.
35. Simor AE, Louie L, Watt C, Gravel D, Mulvey MR, Campbell J, McGeer A, Bryce E, Loeb M, Matlow A. 2010. Canadian Nosocomial Infection Surveillance Program. Antimicrob. Agents Chemother. 54:2265-2268. http://dx.doi.org/10.1128/ AAC.01717-09.
36. Nichol KA, Adam HJ, Roscoe DL, Golding GR, Lagace-Wiens PR, Hoban DJ, Zhanel GG, Canadian Antimicrobial Resistance Alliance. 2013. Changing epidemiology of methicillin-resistant Staphylococcus aureus in Canada. J. Antimicrob. Chemother. 68(Suppl 1):i47-i55. http://dx.doi.org/10.1093/jac/ dkt026.
37. Sader HS, Flamm RK, Farrell DJ, Jones RN. 2012. Activity analyses of staphylococcal isolates from pediatric, adult, and elderly patients:AWARE Ceftaroline Surveillance Program. Clin. Infect. Dis. 55(Suppl 3):S181-S186. http://dx.doi.org/10.1093/cid/cis560.
38. Celikbilek N, Ozdem B, Gurelik FC, Guvenman S, Guner HR, Acikgoz ZC. 2011. In vitro susceptibility of methicillin-resistant Staphylococcus aureus isolates to vancomycin, teicoplanin, linezolid and daptomycin. Mikrobiyoloji Bulteni 45:512-518. (In Turkish.
39. Pitz AM, Yu F, Hermsen ED, Rupp ME, Fey PD, Olsen KM. 2011. Vancomycin susceptibility trends and prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus in clinical methicillinresistant S. aureus isolates. J. Clin. Microbiol. 49:269-274. http://dx.doi.org/10.1128/JCM.00914-10.
40. Mendes RE, Sader HS, Jones RN. 2010. Activity of telavancin and comparator antimicrobial agents tested against Staphylococcus spp. isolated from hospitalised patients in Europe (2007-2008). Int. J. Antimicrob. Agents 36:374-379. http://dx.doi.org/10.1016/j.ijantimicag.2010.05.016.
41. Gales AC, Sader HS, Ribeiro J, Zoccoli C, Barth A, Pignatari AC. 2009. Antimicrobial susceptibility of gram-positive bacteria isolated in Brazilian hospitals participating in the SENTRY Program (2005-2008). Braz. J. Infect. Dis. 13:90-98.
42. Sader HS, Fey PD, Limaye AP, Madinger N, Pankey G, Rahal J, Rybak MJ, Snydman DR, Steed LL, Waites K, Jones RN. 2009. Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006. Antimicrob. Agents Chemother. 53:4127-4132. http://dx.doi.org/10.1128/ AAC.00616-09. (Author Correction, 54:1383, 2010, http://dx.doi.org/10.1128/AAC. 01503-09.
43. Jones RN, Sader HS, Flamm RK. 2013. Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011). 2013. Diagn. Microbiol. Infect. Dis. 75:304-307. http://dx.doi.org/10. 1016/j.diagmicrobio.2012.11.024.
44. Biedenbach DJ, Bell JM, Sader HS, Fritsche TR, Jones RN, Turnidge JD. 2007. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004). Int. J. Antimicrob. Agents. 30:143-149. http://dx.doi.org/10.1016/j.ijantimicag. 2007.03.015.
45. Balode A, Punda-Polic V, Dowzicky MJ. 2013. Antimicrobial susceptibility of gram-negative and gram-positive bacteria collected from countries in Eastern Europe: results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) 2004-2010. Int. J. Antimicrob. Agents 41:527-535. http://dx.doi.org/10.1016/j.ijantimicag.2013.02.022.
46. Asbury WH, Darsey EH, Rose WB, Murphy JE, Buffington DE, Capers CC. 1993. Vancomycin pharmacokinetics in neonates and infants: a retrospective evaluation. Ann. Pharmacother. 27:490-496.
47. Anderson BJ, Allegaert K, van den Anker JN, Cossey V, Holford NH. 2007. Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance. Br. J. Clin. Pharmacol. 63:75-84. http://dx.doi.org/10.1111/j.1365- 2125.2006.02725.x.
48. Alcorn J, McNamara PJ. 2003. Pharmacokinetics in the newborn. Adv. Drug Deliv. Rev. 55:667-686. http://dx.doi.org/10.1016/S0169-409X(03) 00030-9.
49. Bartelink IH, Rademaker CM, Schobben AF, van den Anker JN. 2006. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin. Pharmacokinet. 45:1077-1097. http://dx.doi.org/10.2165/00003088-200645110-00003